Indeed, Cawley et al. recently found that ubiquitin C-terminal hydrolase-L1 (UCHL1) was overexpressed in the cerebrospinal fluid of patients with NPC, and that this was reduced in response to treatment with miglustat [88] UCHL1 is a protein that is mainly expressed in the brain and functions as a deubiquitinating enzyme, cleaving the binding of ubiquitin to ubiquitinated proteins [104,105]. The gene discussed is UCHL1; the disease is nasopharyngeal carcinoma.